SELE抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07570(SELE Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07570(SELE Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

SELE, also known as E-selectin or CD62E, is a cell adhesion molecule expressed on activated endothelial cells. It belongs to the selectin family, which mediates leukocyte rolling and adhesion to vascular surfaces during inflammatory responses. Discovered in the 1980s, SELE is encoded by the *SELE* gene and functions as a transmembrane glycoprotein. Its expression is induced by pro-inflammatory cytokines like TNF-α and IL-1β, making it a key marker of endothelial activation in conditions such as atherosclerosis, sepsis, and cancer metastasis.

SELE antibodies are tools used to detect or inhibit E-selectin in research and clinical contexts. In research, they help study leukocyte-endothelial interactions, inflammation mechanisms, and tumor microenvironment dynamics. Clinically, anti-SELE antibodies have therapeutic potential; for instance, they may block leukocyte recruitment in chronic inflammation or disrupt metastatic cancer cell adhesion. Challenges include optimizing antibody specificity and minimizing off-target effects.

Overall, SELE antibodies bridge basic understanding of vascular biology and therapeutic innovation, offering insights into inflammatory diseases and cancer progression while guiding targeted treatment strategies.